SORANIB inhibits multiple intracellular and cell surface kinases, including VEGFR, PDGFR, and RAF kinases. It prevents tumour cell proliferation and blocks angiogenesis.
Recommended for:
Advanced renal cell carcinoma (RCC)
Hepatocellular carcinoma (HCC)
Differentiated thyroid cancer refractory to radioactive iodine
Patients not responding to chemotherapy
Metastatic or unresectable renal cell carcinoma
Unresectable hepatocellular carcinoma
Radioiodine-resistant differentiated thyroid carcinoma
SORANIB is typically administered as 400mg daily in two divided doses, taken without food or with a low-fat meal. The dosage should be adjusted based on the patient’s clinical response and tolerability, under supervision of an oncologist.
Contraindications:
Hypersensitivity to Sorafenib
Severe hepatic impairment
Pregnancy and breastfeeding
Paediatric patients
Side Effects:
Diarrhoea, nausea, appetite loss
Hand-foot skin reaction
Hypertension
Fatigue
Rash and other dermatologic issues
Rare: bleeding events, cardiac disturbances
